Research
Hormonal
Hyperinsulinemia and hyperglycemia directly increase resistin mRNA expression and serum levels in wild-type mice, indicating that insulin and glucose are key regulators of resistin production.
High insulin and glucose levels directly stimulate the production of resistin. Managing blood sugar and insulin levels through diet and exercise can help keep resistin levels in check.
GoodSupportsHIGH confidence
Resistin mRNA level was increased by 20% in response to hyperinsulinemia and was further increased by 25% in response to hyperglycemia... Similarly, both insulin and glucose increased serum resistin level
Why this rating
High-quality animal study using clamp techniques to isolate insulin and glucose effects.
Source
Regulation of Resistin Expression and Circulating Levels in Obesity, Diabetes, and Fasting
Michael W. Rajala et al. · Diabetes · 2004
DOI 10.2337/diabetes.53.7.1671
mechanism_onlyCited 350×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In obese and diabetic rodent models, circulating resistin levels are elevated and positively correlated with insulin, glucose, and lipids, despite suppressed resistin mRNA expression in adipose tissue, indicating that nutritional regulation of resistin is mediated by insulin and glucose.Good
- Leptin treatment reduces serum resistin and resistin mRNA expression in obese mice, an effect that is independent of weight loss or food intake, suggesting leptin directly regulates resistin to improve insulin sensitivity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →